IGF2BP3 and central nervous system cancer: Similarly, the DNA demethylation in the promoter region of IGF2BP3 could influence the progression of G-CIMP gliomas (67), and cg07166550/ALKBH5 could be used as prognostic biomarkers in prostate cancer (68).